Liver Health Advocacy to Improve the Lives of Persons With Liver Disease

Nov 07 2026
Convention Center: Mile High Ballroom 2B-3B
3:45 PM - 4:45 PM

World Class Speakers

Julius M Wilder

Presenter
Julius M Wilder, MD, PhD, FAASLD

Erika Miller

Presenter
EM

Brian J McMahon

Panelist
Brian J McMahon, MD, FAASLD

Ponni V. Perumalswami

Panelist
Ponni V. Perumalswami, MD, , FAASLD

Norah Terrault

Panelist
Norah Terrault, MD, MPH, FAASLD

Robert Gish

Panelist
Robert Gish, MD, FAASLD

Erika Miller

Panelist
EM

Matthew R D'Uva

Panelist
Matthew R D'Uva

Julius M Wilder

Moderator
Julius M Wilder, MD, PhD, FAASLD

Rotonya Carr

Moderator
Rotonya Carr, MD, FACP, FAASLD

Description

The American Association for the Study of Liver Diseases Public Policy Committee explores challenges for liver health professionals within the health policy landscape, with particular emphasis on physician reimbursement, National Institutes of Health funding, vaccines and hepatitis B, and the Cure Hepatitis C Act of 2025. 

Presentations

3:45 PM - 3:50 PM
Convention Center - Mile High Ballroom 2B-3B

Introduction: American Association for the Study of Liver Diseases Public Policy Committee Chair

Julius M Wilder, MD, PhD, FAASLD | Presenter
3:50 PM - 4:00 PM
Convention Center - Mile High Ballroom 2B-3B

Policy 101: The Impact of the Political Landscape on Hepatology Care and Reimbursement

Erika Miller | Presenter
4:00 PM - 4:45 PM
Convention Center - Mile High Ballroom 2B-3B

Panel Discussion on the National Institutes of Health Research Funding Policy, Health Equity in Liver Disease Policy, the New World Health Organization Designation for Liver Diseases, and Physician Reimbursement

Julius M Wilder, MD, PhD, FAASLD | Moderator

Objectives

  • Explore the vital roles engagement in health policy and collaboration with political leaders play in advancing liver disease clinical care and research.
  • Describe the development of and progress toward implementation of the Cure Hepatitis C Act of 2025.
  • Identify key policy issues around the new hepatitis B virus guideline vaccine policy.
  • Explore the future policy priorities for the American Association for the Study of Liver Diseases (AASLD) including, National Institutes of Health funding, physician reimbursement, World Health Organization designation of liver disease as a recognized noncommunicable disease, and incorporation of core AASLD values (such as equity) into AASLD health policy work.

Copyright © 2026 American Association for the Study of Liver Diseases

AASLD 2026